About us

Phillip (Phil) D. Hustad, Ph.D., is a industrial polymer scientist with a passion for sustainability. He co-founded orgaNX after a 20+ year career in the chemical industry. He is currently CTO of Geminatio, a technology startup developing & delivering materials and infrastructure that enable low-cost integrated circuit shrink paths.

Phil holds 96 US Patents with >100 pending published applications and has coauthored three book chapters and more than 40 journal publications. His research has been featured 5 times in Chemical & Engineering News, including a highlight in the 2006 Year in Review Special Issue. He is a recipient of the 2010 AIChE Industrial R&D Award and several Dow awards, including Dow’s Excellence in Science Award, a 2017 Dow Performance Silicones Technical Achievement Award, a Core R&D Team Technical Award, and the 2014 Electronic Materials Community Award. Technology he coinvented has received two R&D 100 Awards and an ICIS Innovation Award.

In addition to innovation, Phil is also a strong ally and advocate for Diversity, Equity, and Inclusion (DEI) initiatives. He was a founding member of 3M Corporate Research Division’s DEI team and steering committee member for 3M’s Womens’ Leadership Forum Group focused on retention and advancement of women on the technical career path. He also served on the Steering Team for Dow’s Women’s Innovation Network and was recognized as one of Dow’s 6 worldwide Women’s Champions in 2018.

Jason (Jay) A. Barron, Ph.D., J.D. is the General Counsel and a founder of orgaNX. His legal practice focuses on corporate intellectual property development. Jay provides innovative strategies and tactics fto companies to allow them to harness, manage and enforce their IP. Jay’s areas of expertise include patent and trademark prosecution, IP litigation, competitive IP analyses, portfolio management, trade secret program development, and IP transactions.

Jay has both extensive in-house and firm experience counseling multinational companies, universities, research institutions, and startups across technology areas such as life science, biotechnology, pharmaceutical, chemical, and material science. Particular areas of focus include imaging and diagnostics, inorganic and organic chemistry, immunoassays, pharmaceuticals (large and small molecule), analytical instruments, and medical devices.

Jay received his J.D. from Georgetown University Law Center and his Ph.D. in Chemistry and Chemical Biology from Cornell University. Before joining McAndrews, he worked in-house at a number of companies, including Acer Therapeutics (now Zevra Therapeutics), a start-up focused on developing pharmaceuticals to treat serious rare diseases, Beckman Coulter Diagnostics, and Corning Incorporated.